IIT Kharagpur has successfully commercialised its flagship healthcare product COVIRAP the novel diagnostic technology to zero on infectious diseases including Covid-19, the institute said Wednesday.
The product, developed by lead researchers Professor Suman Chakraborty, Dr Arindam Mondal and their research group, has been licensed for commercialisation to the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.
The product, developed by lead researchers Professor Suman Chakraborty, Dr Arindam Mondal and their research group, has been licensed for commercialisation to the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA.
A virtual press meet was organised on Wednesday by the institute in which the researchers were present along with the institute director to make the announcement.
“The above move has taken place at a critical juncture when the recent spurt in Covid-19 infection, commonly known as the second wave, has been threatening to spread more rapidly than ever before,” IIT Kharagpur Director Prof V K Tewari said.
“Moreover, the commercialisation of COVIRAP will initiate complete indigenisation and availability of a large range of affordable healthcare products in the Indian market as well as deep trenches of a large global market that is literally starving for the need of such technology,” Tewari said.
